ALAMEDA, Calif.--(BUSINESS WIRE)--Arriva Pharmaceuticals, a biopharmaceutical company focused on developing anti-inflammatory therapies, announced today that it had been granted a patent in the U.S. related to a fusion protein with potential applications for treating respiratory diseases. The patent (United States Patent 7,247,704) covers compositions of matter and uses of Aeriva™, a fusion protein that combines Secretory Leukocyte Protease Inhibitor (SLPI) and recombinant alpha 1-antitrypsin (rAAT). A similar patent was recently granted by the European Patent Office and will soon issue in several European countries, including the United Kingdom, France and Germany.
